HiDiamond Biotechnology

Explore the latest insights on HiDiamond Biotechnology and its impact on China’s pharmaceutical industry. Fineline Info & Tech delivers reliable data, news, and intelligence to help you navigate the complexities of HiDiamond Biotechnology’s developments with precision and clarity. Stay informed and enhance your decision-making at flcube.com.

Company

Dizal Pharmaceutical Reports First‑Ever Profit as AstraZeneca’s USD 600 Million Sunvozertinib Deal Drives 714% Revenue Surge

Dizal Pharmaceutical Co., Ltd. (SHA: 688192) released its Q3 2026 financial report, posting revenue of RMB 4.770 billion for the first nine months of the year – a 714% year‑on‑year…

November 2, 2026

Alphamab Oncology Doses First Patient in Phase III Trial of JSKN033 – World’s First High‑Concentration Subcutaneous HER2 ADC/PD‑L1 Fixed‑Dose Combination for Recurrent Cervical Cancer

October 29, 2026

Junshi Biosciences Converts Loqtorzi Urothelial Carcinoma Indication to Full Approval; Subcutaneous Toripalimab (JS001sc) NDA Accepted in First‑Line HER2‑Expressing Disease

October 29, 2026

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.

Explore Now

Company Deals

Nerviano Medical Sciences and HiDiamond Biotechnology Sign Collaboration and License Agreement for NMS‑173 – Covalent Second‑Generation mIDH1/2 Dual Inhibitor

October 12, 2026